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1. Introduction 
Tumorigenesis has a complex pathogenesis; with multiple genetic, proliferative, apoptotic 
and differentiation pathways aiding in development and growth of a tumor. Conventional 
chemotherapy has been the backbone for cancer treatment. The chemotherapeutic agents act 
on different phases of cell cycle of rapidly proliferating cells. Subsequently, in addition to 
effect of cancerous cells they also affect rapidly multiplying gastrointestinal lining cells, 
bone marrow and hair follicles leading to mucositis, diarrhea, various degrees of 
myelosuppression and alopecia. The search for less toxic agents has been ongoing for 
decades. Targeted therapy refers to directing a drug to a target that is either specific to or 
over expressed on the malignant cell. The concept of targeted therapy dates back to Paul 
Ehrlich who used the term “magic bullets” to describe a therapeutic agent which killed the 
microorganism but left the patient unharmed. Today the concept of targeted therapy is the 
most rapidly evolving field in drug discovery and cancer treatment.   
One of the major hallmarks of successful targeted treatment is use all trans-retinoic acid 
(ATRA) for acute promyelocytic leukemia (APL). APL is distinguished by translocation 
between chromosome 15 and 17 (PML-RAR-ǂ) which halts the differentiation at 
promyelocyte stage. ATRA induces the differentiation of promyelocytes into mature 
myeloid cells. Use of ATRA has improved response rate and survival rate in APL which was 
previously associated with a significantly worse outcome. In this chapter we review other 
major targeted agents. Due to limited space we emphasized primarily on chronic myeloid 
leukemia, multiple myeloma and lymphoma. 
2. Chronic myeloid leukemia  
Chronic myeloid leukemia (CML) is other example for successful targeted therapy 
treatment. The initial description of chromosome abnormality was first described by Nowell 
and Hungerford in two patients who were noted to have a loss of the long arm of 
chromosome 21 or 22 (later confirmed to be chromosome 22 and designated Philadelphia 
chromosome (Ph))(Nowell and Hungerford 1960; Nowell and Hungerford 1961). 
Subsequently, Rowley discovered that there is a reciprocal translocation between 
chromosome 9 and 22 in these patients(Rowley 1973). As a result of the translocation, 
cellular oncogene ABL on chromosome 9 and a segment of chromosome 22, the breakpoint 
cluster region BCR, fuse and cause activation of tyrosine kinase which is capable of inducing 
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the disease in mice. This established the fusion protein as the cause of malignant 
transformation in this disease. This led to the development of small molecule inhibitors of 
the mutant kinase and led to the discovery of Imatinib mesylate (Gleevec; Novartis, Basel, 
Switzerland).  
Imatinib was the first tyrosine kinase inhibitor (TKI) to be developed and approved for CML 
in 2002. It was developed on the concept of designing synthetic compounds with chemical 
structures that are able to compete with the binding site in the kinase domain. Imatinib has 
demonstrated higher response rates (RR) and better tolerability compared to interferon and 
low dose cytarabine (Internation Randomised Study of Interferon and ST1571 (IRIS) trial) 
(Santos and Quintas-Cardama 2011). Recent update of IRIS trial reported that at 8 years 
follow up 83% had complete cytogentic response (cCR) and overall survival (OS) was 85% 
among patients with newly diagnosed, untreated CML in chronic phase (American Society 
of Hematology, 2009, Abstract 1126). Authors did report that 45% of patients in Imatinib 
arm discontinued treatment and one of the major reasons was development of resistance 
(Deininger M et al 2009). Over expression of the BCR-ABL1 oncogene, mutations in BCR-
ABL1 that obstruct imatinib binding, alternative signaling pathways which reduce levels of 
transporters responsible for imatinib uptake have been associated with resistance. Second 
generation TKI approved in for patients with imatinib-resistant CML or imatinib intolerant 
are dasatinib (Sprycel; Bristol-Myers Suibb) and nilotinib (Tasigna; Novartis) and are highly 
active against most BCR-ABL1 mutations. Moreover, recently results of two phase III 
randomized trials comparing them to imatinib as first-line treatment showed higher major 
cytogenetic response (MCyR), major molecular response (MMR) and reduced rates of 
transformation to accelerated phase (AP) or blast phase (BP)(Kantarjian, Giles et al. 2007; 
Hochhaus, Baccarani et al. 2008).  As a result, U.S. Food and Drug Administration (FDA) 
approved both dasatinib and nilotinib as first line therapies for patients with CML in 
chronic phase (CP).  
There are patients who continue to experience poor outcomes despite the development of 
second generation TKIs. T315I mutation is the one of major cause of this resistance. 
Furthermore, none of the first and second generation TKIs eliminate leukemic stem cells 
(LSCs).  A fraction of LSCs persist in a quiescent state and are seen in patient with CML in 
cCyR. It is believed that they are responsible for CML relapse upon discontinuation of 
imatinib therapy.  
2.1 Newer agents in CML treatment 
New drugs have been developed with special interest in agents active in highly TKI-
resistant CML (Table 1). 
3. Multiple myeloma  
Multiple myeloma (MM) is a B-cell neoplasm that is characterized by clonal proliferation 
of terminally differentiated plasma cells. Clinical features include bone disease, 
hypercalcemia, cytopenias, and renal dysfunction. Our understanding of this disease has 
improved significantly in the past decade and has lead to the development of novel 
targeted therapies. The interaction between MM cells and their microenvironment is the 
subject of intense research and several novel targets have emerged(Hideshima, Mitsiades 
et al. 2007).  
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Drug 
Study 
Phase 
Comments Clinical trial* 
Panotinib II 
Third generation TKI which 
acts against T315I mutation 
NCT01207440 
Danusertib II 
Inhibits Aurora kinase and 
BCR-ABL1 (includes T315I 
mutation) 
NCT00335868 
XL-228 I 
Inhibits Aurora kinase and 
BCR-ABL1 (includes T315I 
mutation) 
NCT00464113 
AT-9283 I 
Inhibits Aurora kinase and 
BCR-ABL1 (includes T315I 
mutation) 
NCT00522990 
DCC-2036 I Switch pocket inhibitor NCT00827138 
BMS-214662 I Farnesyl transferase inhibitor NCT00006213 
Panobinostat I/II Histone deacetylase inhibitor NCT00686218 
Omacetaxine I/II 
Homoharringtonine 
formulation- disrupts 
protein synthesis 
NCT00462943 
NCT00375219 
NCT00006364 
* Clinicaltrials.gov accessed on 4/30/11 
Table 1. Lists the newer promising agents currently in preclinical or clinical phase of 
development for treatment of CML. 
3.1 Intracellular and nuclear targets 
3.1.1 Proteasome inhibitors  
The proteasome is an abundant catalytic complex that is found in both the nucleus and 
cytoplasm of eukaryotic cells (Adams 2004). Its function is to degrade intracellular 
proteins,such as the cyclins, caspases, BCL2 and NF-κB, which mediate cell cycle 
progression and apoptosis. The mechanisms by which malignant cells are more susceptible 
to proteasome inhibition than normal cells are not completely understood. One explanation 
is that many types of malignant cells rapidly proliferate and have one or more aberrant cell-
cycle checkpoints. These cells might accumulate defective proteins at a higher rate than 
normal cells, which increases their dependency on the proteasome as a disposal mechanism. 
Inhibition of proteasome function would lead to a progressive accumulation of these 
proteins and could trigger apoptosis. In addition, NF-κB activation pathway has been 
associated with MM and has been linked to drug resistance. Proteasome inhibition might 
make malignant cells more sensitive to apoptosis by death-inducing ligands (Jeremias, 
Kupatt et al. 1998).  
Bortezomib (Velcade, Millenium Pharmaceuticals, Country) was the first proteasome 
inhibitor to be widely used in the management of MM. It is a boronic acid dipeptide that 
reversibly inhibits chymotryptic-like activity of the proteasome and blocks the NF-κB 
pathway. Bortezomib treatment also leads to downregulation of transcripts that are 
associated with growth and survival pathways (e.g. IGF-1 pathway) and upregulation of 
transcripts involved in both of the main pro-apoptotic pathways (Mitsiades, Mitsiades et al. 
2002). In MM cells, bortezomib inhibits DNA repair and induces p53 by phosphorylation 
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and degradation of MDM2, through activation of caspase-3 by caspase-8.  Bortezomib also 
inhibits MM- bone marrow stromal cell (BMSC) interactions(Mitsiades, Mitsiades et al. 
2002), expression of phosphorylated VEGF-induced caveolin-1, ICAM-1, VCAM-1(Kastritis, 
Charidimou et al. 2009).  
The antimyeloma activity of bortezomib was confirmed in a phase II study (CREST)  
in relapsed or refractory MM patients (Richardson, Barlogie et al. 2003; Jagannath, Barlogie 
et al. 2008). Bortezomib was administered with or without dexamethasone and a response 
was seen in 35% with a complete response (CR) in 7 patients and a near complete response 
(nCR) in 12 patients. Subsequently a phase III randomized study in relapsed MM 
(Richardson, Sonneveld et al. 2005) demonstrated a RR of 43% with 9% CRs. These findings 
led to the approval of bortezomib by the FDA for relapsed or refractory myeloma. Studies of 
bortezomib in front line setting have demonstrated higher RR (Harousseau, Attal et al.  
2010) in the bortezomib combination arm and continued to remain higher after transplant as 
long as patients have achieved at least very good partial response (VGPR). This and  
other studies have found that bortezomib remains superior in patients with high-risk 
disease (elevated ǃ2-microglobulin, deletion of chromosome 13, t (4;14), and del p53)  
(Cavo M 2007; Harousseau, Attal et al. 2010). Bortezomib based regimens have also been 
found to be effective as front line treatments in transplant ineligible patients (Mateos, 
Hernandez et al. 2006).  
As more data emerged about the effects of proteasome inhibition on MM cells several 
studies of combining bortezomib with other agents were designed. These were initially 
studied in the preclinical setting based on synergistic rationale and several of these are now 
being studied in the clinical setting.  
 Several second generation proteasome inhibitors are currently being studied for their  
role in treatment of MM. Carfilzomib is an irreversible proteasome inhibitor that binds  
to ǃ5 subunit of the 20S proteasome (Kuhn, Chen et al. 2007).  Multiple pathways  
are implicated in the programmed cell death of MM cells when exposed to carfilzomib 
(Kuhn, Chen et al. 2007). Carfilzomib has been studied in relapsed/refractory multiple 
myeloma patients demonstrating a 26% RR (S. Jagannath 2009). In another phase II study 
comparing bortezomib exposed and naïve patients, the naïve patients had a greater RR 
(57%) (R. Vij 2009). 
Other proteasome inhibitors CEP 18770, Marizomib and MLN 9708 are also currently being 
evaluated in phase I and II studies (www.clinicaltrials.gov ; Chauhan, Catley et al. 2005; 
Piva, Ruggeri et al. 2008). Marizomib (NPI-0052) is an orally active proteasome inhibitor that 
acts by a different mechanism to inhibit the proteasome. Marizomib has been shown to be a 
more potent inhibitor of the NF-κB and other cytokines (Chauhan, Catley et al. 2005) than 
Bortezomib. It interferes with the chymotryptic-like, tryptic-like and caspase-like proteolytic 
activity of the proteasome, while bortezomib only interferes with the chymotryptic-like.  It 
has also been shown to overcome bortezomib resistance both in vitro and in vivo. Studies are 
currently evaluating Marizomib as a single agent as well as in combination with bortezomib 
where a synergistic effect has been seen (Chauhan, Singh et al. 2008).  
3.1.2 Immunomodulatory drugs 
Immunomodulatory drugs (IMids) including thalidomide (Thal) and lenalidomide (Len) are 
commonly used in the treatment of MM (Rajkumar 2011). Multiple mechanisms have been 
proposed including effects on angiogenesis, cytokine production, direct antineoplastic 
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effects, anti-inflammatory effects, sensitization of MM cells to apoptosis and interaction with 
bone and micro-environment (D'Amato, Lentzsch et al. 2001; Mitsiades, Mitsiades et al. 
2002). IMiDs may have direct antineoplastic effects by blocking signaling through NF-κB 
signaling, which is universally activated in MM cells and may induce apoptosis via the 
caspase-8/death receptor pathway (Lacy 2011). Pamilidomide and Len also cause cell cycle 
arrest in plasma cells by p21 WAF-1 activation, which is p53 independent, suggesting 
possible efficacy in cancer with p53 mutation and deletion (Escoubet-Lozach, Lin et al. 2009). 
They also have potent immunomodulatory properties including augmentation of natural 
killer cell activity and stimulation of cytotoxic T cells (Haslett, Corral et al. 1998; Corral, 
Haslett et al. 1999).  
Thal is a synthetic glutamic acid derivative that was the first agent in this class to be used to 
treat MM because of its antiangiogenic properties. In relapsed myeloma, Thal and 
dexamethasone have RR of 40 to 50% (von Lilienfeld-Toal, Hahn-Ast et al. 2008). Len was 
approved by the FDA based on results from phase III studies that showed a combination of 
Len and high dose dexamethasone was superior to dexamethasone alone (Dimopoulos, 
Spencer et al. 2007; Weber, Chen et al. 2007). The RR was 60% in the Len group as compared to 
24% in the placebo group. A significant difference was also seen in the time to progression 
(TTP) (11.3 months vs 4.7 months) and OS (HR 0.66). Comparison of Len with high or low 
dose dexamethasone showed that the low dose dexamethasone is safer and associated with 
improved survival in patients with newly diagnosed MM (Rajkumar, Jacobus et al. 2010).  A 
subsequent phase I/II study evaluated the combination of Len, bortezomib and 
dexamethasone in newly diagnosed MM and reported partial response (PR) was 100% with 
74% achieving a VGPR. With a median follow up of 21 months, estimated 18-month 
progression free survival (PFS) and OS for the combination treatment with/without 
transplantation were 75% and 97% respectively. A phase III trial evaluating Len 
/dexamethasone vs bortezomib/ Len /dexamethasone as induction treatment in newly 
diagnosed MM patients who are not candidates for transplant is currently underway 
(www.clinicaltrials.gov). A combination of bortezomib, dexamethasone, Len and 
cyclophosphamide is being studied in a phase I/II trial (EVOLUTION) (Kumar, Flinn et al. 
2010). The overall RR in the phase I portion of this study was 96% with a 68% VGPR or better. 
Len has also shown benefit as maintenance treatment after transplant (Michel Attal 2010; 
Philip L. McCarthy 2010). In the CALGB trial patients who were randomized to receive Len 
(10mg daily) had a median TTP of 42.3 months vs. 21.8 in the placebo arm.  
Pomalidomide is a new Thal derivative and has been shown to be the most potent IMiD 
(Lacy 2011). In addition to mechanisms mentioned above, pomalidomide may have a role in 
preventing or treating myeloma bone disease via effects on osteoclasts (Anderson, Gries et 
al. 2006). A phase II study using pomalidomide and dexamethasone in a relapsed/refractory 
multiple myeloma showed a RR of 63% (33% CR or VGPR) (Lacy, Hayman et al. 2009). The 
median PFS in this study was found to be 11.6 months irrespective of risk factors. This and 
other studies seem to suggest that pomalidomide is active in patients that are refractory to 
Len and those who have high risk molecular markers. 
3.1.3 Heat shock protein 90 (HSP 90) inhibitors 
HSP90 is a molecular chaperone that is induced in response to cellular stress and stabilizes 
client proteins involved in cell cycle control and proliferative/anti-apoptotic signaling.  It 
facilitates the folding and stability of numerous signaling molecules that control the growth 
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and survival of cancer cells (Whitesell and Lindquist 2005). HSP 90 is a key molecular 
chaperone for signal transduction proteins critical to MM cell growth and survival and drug 
resistance. MM cells produce a large quantity of immunoglobulins that are folded into 
tertiary structures in the endoplasmic reticulum. HSP90 plays a large role in chaperoning 
these proteins into formation and disposing of misfolded proteins. HSP90 inhibitors 
interrupt this chaperoning activity, which leads to accumulation of misfolded proteins, 
endoplasmic reticulum stress, and ultimately apoptosis (Davenport, Moore et al. 2007; 
Mitsiades, Hideshima et al. 2009; Chanan-Khan, Borrello et al. 2010).  
Tanespimycin (KOS-953) is one of the HSP90 inhibitor and acts mainly through the 
inhibition of ATPase activity of HSP90. HSP90 inhibition increases the bortezomib induced 
apoptosis in MM cells by blocking the HSP90 stress response. Preclinical data has shown 
that tanespimycin may also be protective against the peripheral neuropathy associated with 
bortezomib. A phase I/II study evaluated bortezomib followed by tanespimycin in 
relapsed/refractory MM (P. G. Richardson 2009) and reported RR were 41%, 20% and 14% 
in the bortezomib-naïve, bortezomib-pretreated and bortezomib-refractory patients 
respectively. Several other HSP90 inhibitors are currently in early phase trials to evaluate 
their response in myeloma.  
3.1.4 HDAC inhibitors 
Eukaryotic DNA is packed in a high level structure called chromatin. Expression of genes is 
controlled by the interaction between the negatively charged phosphate groups on DNA 
and the positively charged amine groups on the lysine and arginine amino acids on histone 
terminal tails. The N-e-acetylation of lysine residues found in histones is equilibrated by two 
enzymes: the histone acetyl transferases (HAT) and the histone deacetylases (HDAC). 
HDAC inhibitors result in an increase in acetylation of histones which in turn promotes the 
re-expression of silenced regulatory genes. These compounds represent a family of small 
molecule-based anti-cancer therapies.  
Currently several HDAC inhibitors are being studied as single agents or in combination 
with other agents mainly bortezomib and Len. Vorinostat is an oral HDAC inhibitor that is 
currently being used in the treatment of T-cell lymphoma. It downregulates IGF-1 and IL6 
signaling pathways as well as DNA synthesis and repair enzymes (Mitsiades, Mitsiades et 
al. 2004). Vorinostat is also being studied in combination with bortezomib based on 
preclinical studies which suggest synergistic anti-MM activity.(Mitsiades, Mitsiades et al. 
2004). Phase I studies combining bortezomib and vorinostat have shown (Badros, Burger et 
al. 2009) RR of 42% including 3 PRs among 9 bortezomib refractory patients.  Further studies 
with vorinostat in combination with other agents are currently ongoing.  
Panobinostat (LBH589) is a potent pan-deacetylase inhibitor that disrupts aggresome and 
HSP 90 function via inhibition of HDAC6, promoting cytotoxic misfolded protein 
aggregates and MM cell death. It is currently being tested in combination with other 
therapies for relapsed/refractory MM. In a phase Ib trial responses were observed in 68% of 
patients across all cohorts and in 62% of bortezomib refractory patients. (M. Alsina 2010). 
Several other phase I and I/II trials have shown similar responses in relapsed/refractory 
MM in combination with Len  and melphalan (M Mateos 2010) prednisone and Thal 
(Massimo Offidani 2010). Currently phase II trials are ongoing comparing a combination of 
Panobinostat/Bortezomib/Dexamethasone vs Bortezomib/Dexamethasone in 
relapsed/refractory MM. Overall panobinostat in combination with other agents has shown 
encouraging anti-myeloma activity however further studies are needed to establish its role 
in treatment of MM. 
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Other HDAC inhibitors currently being evaluated in the treatment of MM are romidepsin, 
belinostat, ITF2357 and AR 42.  
3.1.5 AKT 
The Phosphoinositide 3 Kinase (PI3K)/protein kinase B(AKT) pathway is a central signaling 
pathway in several cellular functions including proliferation, growth, survival and 
migration. AKT is activated by PI3K and in turn activates several downstream targets.  AKT 
activation has been reported to induce growth and survival advantage to MM cells through 
GSK-3ǃ and mTOR phosphorylation. AKT activation has been shown to be associated with 
advanced stage and poor prognosis in MM patients and also resistance to dexamethasone in 
MM cells. Targeting the PI3K/AKT pathway is being studied in hematological malignancies 
(Kawauchi, Ogasawara et al. 2009).  
Perifosine (KRX-0401) is a synthetic novel oral alkylphospholipid that inhibits both 
constitutive and cytokine induced AKT activation and januskinases (JNK) activation leading 
to apoptosis of MM cells including those adhering to bone marrow stromal cells (BMSC) 
(Mitsiades, Hideshima et al. 2009). In a phase I/II study adding perifosine to bortezomib 
and dexamethasone treatment showed  an RR of 38% and OS of 16 months in the 
bortezomib-refractory group and an RR of 55% and a median OS that is not reached in the 
bortezomib-relapsed group (Paul Richardson 2009). Currently there is a phase III trial 
recruiting patients with MM pretreated with bortezomib, to be randomized to bortezomib-
dexamethasone and perifosine or placebo (NCT01002248).  
3.1.6 Mammalian target of rapamycin (mTOR)  
The mammalian target of rapamycin (mTOR) is an intracellular kinase that controls the 
production of proteins through regulation of their translation. mTOR is activated by AKT 
and regulates cell growth, proliferation, motility, survival and metabolism. mTOR exerts its 
downstream effects through the formation of protein complexes called mTORC1 and 
mTORC2. The PI3K/AKT pathway is commonly activated in human cancer and active AKT 
promotes mTORC1 signaling by phosphorylating and inhibiting the tuberous sclerosis1/2 
(TSC1/TSC2) negative regulatory complex(Dowling, Topisirovic et al. 2010). mTOR acts as a 
neoplastic switch that is frequently turned on by many mutations found in cancer, and its 
inhibition offers a promising target.  
Temsirolimus is an analogue of the rapamycin that acts by binding to FKBP-12, an 
intracellular protein, and the FKBP-12-temsirolimus complex inhibits mTOR activity in the 
PI3K-AKT pathway. In addition to renal cell carcinoma temsirolimus is being investigated 
in MM and other cancers. A phase II study (Farag, Zhang et al. 2009) reported an overall RR 
of 38% (1 PR, 5 MR). Another phase I/II study reported 33% overall RR combining 
temsirolimus with bortezomib (Ghobrial, Weller et al. 2011). Other mTORs including 
everolimus and ridaforolimus are currently being studied in MM (www.clinicaltrials.gov). 
Emerging data has shown that rapamycin analogs do not appear to be effective as 
monotherapies (Dowling, Topisirovic et al. 2010). Rapamycin treatment leads to 
hyperactivation of AKT through loss of the mTORC1/S6k1/IRS-1/PI3K negative feedback 
loop. In addition to this mTORC2 is rapamycin insensitive and is known to cause AKT 
phosphorylation. A majority of the first generation mTOR inhibitors that do not inhibit 
mTORC2 are thus not as effective as previously thought, but their use in combination with 
other agents can overcome these resistance mechanisms. This serves as the rationale for 
 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
262 
Target  Drug Study phase Comments
Farnesyl 
transferase 
Tipifarnib 
(Zarnestra) 
II FTI inhibitors prevent the farnesylation of 
Ras. Preclinical models have shown a 
synergism with bortezomib. 
Bcl2 Obatoclax
ABT737 
I/II
Preclinical 
Bcl2 prevents cell death by inhibiting 
adapter molecules involved in the activation 
of caspases in intrinsic pathway. It is 
overexpressed in most human tumor types.   
Aurora A  
 
Aurora B 
MLN 8237
ENMD-2076 
TAK 901 
I/II
I 
I 
The aurora kinases regulate cell cycle transit 
from G2 through to cytokinesis. Aurora 
kinase inhibitors have been shown to inhibit 
MM cells.
P38 MAPK SCIO 469 II MAPK is a signaling protein that is 
important in cell proliferation. In 
combination with bortezomib an ORR of 
32% with 9% stable disease in rel/ref MM.  
Kinesin 
spindle 
protein 
ARRY 520 I/II KSP is required for cell cycle progression 
through mitosis. KSP inhibition arrests cells 
in mitosis, resulting in cell death and KSP 
inhibitors target proliferating cells.  
Multiple 
kinases 
Plitidepsin 
(Aplidin) 
Curcumin 
Sorafenib
III
II 
I/II 
Plitidepsin is a cyclodepsipeptide which 
induces MM cell death by activation of p38 
and c-jun signaling as well as caspase 
activation. A phase II study showed 15% ORR.  
CDK Dinaciclib
PD 0332991 
Flavopiridol 
SNS-032 
Seliciclib 
I
I/II 
I/II 
I 
I/II 
Cyclin dependant kinases (CDKs) are a 
family of protein kinases that play a vital 
role in cell cycle regulation. Cyclins D1, D2 
and D3 are dysregulated in all MM cells. 
CDK inhibitors target multiple CDKs as well 
as other targets including RNA polymerase 
II or GSK-3ǃ. CDKIs are being testes as 
single agents or in combination in MM.  
PKC ǃ Enzastaurin II  
MEK 1/2 Selumitinib 
(AZD6244) 
II MEK/ERK pathway activation in MM is 
critical for cell growth and survival. 
AZD6244 has been shown to target both MM 
cells and osteoclasts 
Casein 
Kinase 2 
CX-4945 I  
Telomerase GRN163L I GRN163L is an antisense oligonuleotide that 
binds to, and competitively inhibits 
telomerase. This leads to telomerase 
shortening, cessation of MM cell growth, 
and promotion of apoptosis. 
IKK RTA 402
PS 1145
I
Preclinical
 
eIF5A SNS01-T Preclinical/I  
Table 2. Agents targeting intracellular and nuclear molecules.  
www.intechopen.com
 
Targeted Therapies in Hematological Malignancies 
 
263 
combining mTOR inhibitors with AKT inhibitor perifosine which has shown enhanced 
activity in MM cells (Cirstea, Hideshima et al. 2010). Other combinations of mTOR inhibitors 
with MAPK inhibitors or RAF/VEGF inhibitors are currently being tested in the clinical 
setting. Newer mTOR inhibitors that have activity against mTORC2 may represent agents 
that could be used in combination with other anti-myeloma agents in the future.  
Several other intracellular and nuclear targets are being studied in different stages for MM. 
Some of these are in clinical trials (plitidepsin) while others are still in the preclinical phase 
(IκB kinase (IKK) inhibitors or SNS01-T). More agents that are being tested in multiple 
myeloma are shown in table 2.  
3.2 Cell surface receptors, growth factors and growth factor receptors targets 
3.2.1 EGFR 
The epidermal growth factor (EGFR) is a member of the ErbB family of receptor tyrosine 
kinases and its role in carcinogenesis has been established. Upon ligand binding the EGFR 
homo or heterodimerizes, which in turn stimulates the tyrosine kinase activity and initiates 
cell signaling pathways including mitogen activated protein kinase (MAPK) pathway and 
the PI3 kinase pathway (Mendelsohn and Baselga 2006). EGFR has been shown to be 
expressed on malignant plasma cells of MM and its microenvironment. Inhibiton of EGFR 
signaling has shown to induce apoptosis in MM cells (Mahtouk, Jourdan et al. 2004; 
Mahtouk, Hose et al. 2005).  Cetuximab is a chimeric anti-EGFR antibody that inhibits 
EGFR-ligand interaction and induces cell cycle arrest, apoptosis, and antibody-dependant 
cellular cytotoxicity (ADCC) (Boll, Eichenauer et al. 2010). A phase II trial is currently 
undergoing to evaluate dexamethasone with or without cetuximab in relapsed/refractory 
MM (Boll, Eichenauer et al. 2010).  
3.2.2 IL6 
IL6 is an inflammatory cytokine that activates Jak/STAT pathway by binding to its receptor 
(IL6R). It acts as an antiapoptotic factor for MM cells and also confers drug resistance within 
the bone marrow microenvironment. IL6 also stimulates osteoclastogenesis thereby 
contributing to the development of osteolytic lesions. Siltuximab (CNTO 328) is a chimeric 
monoclonal antibody that is derived from the fusion of the murine variable IL6 binding 
region with human IgG constant domain. Preclinical studies have shown that CNTO 328 
enhances the cytotoxic effects of bortezomib by activation of caspases 3, 8 and 9 (Voorhees, 
Chen et al. 2007). A phase II study combining CNTO 328 and dexamethasone in 
relapsed/refractory MM has shown 57% RR (3CR, 9PR). Antibodies directed against the IL6 
receptor are also currently being studied in MM.  
3.2.3 CS1 
CS1 is a cell surface glycoprotein belonging to immunoglobulin gene superfamily that is 
highly expressed on MM cells (Hsi, Steinle et al. 2008). The role of CS1 is not clear but it may 
promote and supports MM cell adhesion to BMSCs. Anti-CS1 staining was seen in all 
plasmacytomas and bone marrow biopsies. More importantly CS1 staining is not seen on 
normal tissues including CD34 cells. Elotuzumab (HuLuc63) is a humanized monoclonal 
antibody that has shown to induce significant anti-myeloma activity both in vitro and in vivo 
(Hsi, Steinle et al. 2008; Tai, Dillon et al. 2008). A phase I/II study evaluating elotuzumab 
with Len and low dose dexamethasone in relapsed/refractory MM has shown that the 
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combination is relatively safe and a RR of 82% (64%PR, 18% VGPR) (S. Lonial 2010). 
Another phase I study combining elotuzumab with bortezomib (A. J. Jakubowiak 2010) 
demonstrated a RR of 60%. 
3.2.4 CD40 
CD40 is a transmembrane protein belonging to the tumor necrosis factor -ǂ (TNFǂ) family 
and is highly expressed on the surface of MM cell lines and primary MM cells 
(Westendorf, Ahmann et al. 1995).  Binding of CD40 on MM cells with its ligand ,CD40L, 
upregulates the expression of adhesion molecules (e.g. LFA-1 and VLA-4) which further 
enhances the adhesion of MM cells to BMSCs as well as IL-6 and vascular endothelial 
growth factor (VEGF) secretion from BMSCs (Hideshima, Mitsiades et al. 2007). CD40 
activation promotes MM cell growth and migration via PI3K/AKT/NF κB signaling. Anti 
CD40 monoclonal antibodies (SGN-40, CHIR-12.12) have shown anti-MM activity in vitro 
and in vivo (Hayashi, Treon et al. 2003; Tai, Catley et al. 2004). A phase I study of 
dacetuzumab (SGN-40) reported 20% stable disease (SD). Further trials using 
dacetuzumab in combination with other agents including Len are currently underway 
(Edward Agura 2009).  
Several other agents directed against cell surface receptors, growth factors and growth factor 
receptors are listed in table 3. 
4. Targeted therapy in lymphoma 
Despite remarkable advances in diagnostic techniques and treatment, lymphoma remains 
leading cause of cancer-related mortality. Since US Food and Drug Administration (FDA) 
approval in 1997, rituximab has been the mainstream of treatment for non-Hodgkin’s 
Lymphoma (NHL) expressing CD20 antibody on their surface. The surface expression of 
CD20 on B cell lymphoma, and the fact that most NHL’s are B cell has provided 
development of this and many other monoclonal antibodies (mAB) in treatment of this 
group of malignancies.  
To-date there are about six mAB based treatments for hematologic malignancies that have 
been approved by Food and Drug Administration (FDA) in the United States. These mAB 
treatments have improved outcomes and reduced toxicity compared to more conventional 
thermotherapy regimens. In spite of recent advances in mAB development, current 
treatments are not optimally effective; with relapse and resistance to chemotherapy or even 
mAB’s seen commonly and the risk of secondary malignancies is an ongoing concern. Due 
to upcoming more sophisticated and modern molecular techniques new monoclonal 
antibodies targeting CD3, CD4, CD8, CD20, CD22, CD19, CD40, CD52, CD 74 and HLA Drǃ 
has been developed, but only antibody to CD20 on B cells and CD52 on T cells are broadly 
used in clinical practice.  
4.1 Rituximab 
4.1.1 Diffuse large B-Cell lymphoma 
Diffuse Large B-Cell Lymphoma (DLBCL) is the most frequent subtype of NHL in all 
countries around the world and all age groups (Jaffe ES 2001). This aggressive lymphoma is 
potentially curable, but carries a high risk of relapse. Addition of rituximab (R) to standard  
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Target Drug Study phase Comments 
TRAILr Mapatumumab II A humanized mAb for TNF-related apoptosis-
inducing ligand receptor being studied in 
combination with bortezomib because of its ability 
to induce apoptosis. 
VEGF, 
VEGFr 
Bevacizumab 
Vandetanib 
II 
II 
Angiogenesis plays a crucial role in MM regulated 
by interactions between the MM cells and the BM 
microenvironment.  
IGF1, IGF1R AVE 1642 I IGF signaling pathway is important in tumor 
growth invasion and metastasis through the 
Ras/Raf/MEK and PI3K/AKT pathways. Targeting 
this pathway is difficult due to the cross reactivity 
with insulin receptors. 
Hedgehog BMS 833923 Ib BMS 833923 is a small molecule inhibitor of 
Smoothened (SMO), a component of the hedgehog 
(Hh) pathway that plays a role in cell differentiation 
and proliferation. A multiple ascending dose (MAD) 
study is underway.  
CS1 Elotuzumab 
(HuLuc63) 
I/II  
CD 56 BB-10901 
IMGN901 
I 
I 
CD 56 is a membrane glycoprotein that is expressed 
on 70-90% of MM cells. Humanized mAb linked to 
DM1, a cytotoxic maytanisinoid are being studied in 
combination with other drugs.  
PD-1 CT 011 II  
Tyrosine 
kinase 
inhibitors.  
Dasatinib 
Dovitinib (TKI 
258) 
Sunitinib 
 
II 
II 
II 
Several targets of TKIs including Src family kinases, 
PDGFR and cKIT have shown some role in MM 
pathology and these drugs are being studied as 
single agents or in combination with other agents.  
Dovotinib is an inhibitor of the FGF-3 receptor that 
is involved in 10-20% MM patients with t(4;14). 
KIR IPH 2101 II  
RANKL Denosumab I/II  
DKK BHQ880 I/II DKK is a soluble Wnt pathway antagonist that is 
secreted by MM cells and inhibits osteoblastic 
activity and its serum level correlates with osteolytic 
lesions. 
GM2 BIW 8962 I/II  
CD 38 Daratumumab I/II  
MUC1 ImMucin I/II  
CD 74 Milatuzumab I/II  
BAFF LY2127399 
AMG523 
I/II 
Preclinical 
B cell activating factor (BAFF) is derived from 
stromal cells and osteoclasts and its inhibition 
reduces tumor burden and osteolytic lesions in 
preclinical studies.  
CXCR 4 BKT 140 I/II  
CD 138 BT 062 I/II CD 138 is a heparin sulfate proteoglycan that serves 
as a receptor for EGF ligands and is overexpressed 
on MM cells.  
Table 3. Agents targeting cell surface antigens, growth factors/cytokines and growth factor 
receptors. 
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CHOP (cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and 
prednisone) has transformed outcome of DLBCL, and increased cure rate by about 20%.  
A: Previously untreated DLBCL 
The first study was reported by Coiffier et al (Coiffier, Lepage et al. 2002) and was recently 
updated (Coiffier, Thieblemont et al.) in 2010. In this French study, patients with untreated 
DLBCL were randomized to either CHOP or R-CHOP. Event free survival (EFS) was 
significantly improved with addition of R. Higher CR or unconfirmed complete response 
(uCR) was achieved in R arm (76% Vs 63%). Survival also improved by 13% (70% compared 
to 57%) at 2 years in the R arm. This benefit was independent of international prognostic 
index (IPI) and age. Recent update of this study confirmed improvement in PFS and OS at 
10years in the R combination arm (PFS 36.5%, vs 20%, OS 43.5% vs 27.6%). (Coiffier, 
Thieblemont et al.) 
ECOG 4494 (Habermann, Weller et al. 2006) trial evaluated the role of R in induction and 
maintenance treatment of untreated DLBCL patients. Two year failure free survival (FFS) 
rate was significantly higher in maintenance R arm (MR) (76% vs 61%) however there was 
no significant OS benefit. In addition patients who received R in induction phase did not 
benefit from MR. In a secondary analysis, patients who received R-CHOP as induction had 
longer three year FFS (52% vs 39%) as well as OS (67% vs 58%). 
Role of R in good-risk younger patients was reported by the Mabthera International Trial 
group (Pfreundschuh, Trumper et al. 2006). In that trial patients assigned to R-
chemotherapy arm had significantly improved three year event free survival (EFS) (79% vs 
59%) and OS (93% vs 84%). On long term follow up there was continued benefit in EFS 
(Pfreundschuh M 2010). Data in younger patients with high risk features is lacking, simply 
due to fact that this patient population is best served with autologous transplant in first CR 
(Milpied, Deconinck et al. 2004). S9704 (South West Oncology Group), a phase III 
randomized trial addressing that question, has completed accrual and results are expected 
to be presented soon. 
B. Relapsed DLBCL 
R has improved response rates of salvage regimens like ICE (ifosfamide-carboplatin-
etoposide) (Kewalramani, Zelenetz et al. 2004) and DHAP (cisplatin-cytosine arabinoside-
dexamethasone) (Witzig, Geyer et al. 2008). A recent trial evaluated R-ICE vs R-DHAP 
followed by autologous stem-cell transplant (ASCT) and then again randomized to R 
maintenance or observation (Gisselbrecht, Glass et al.). R-ICE or R-DHAP had similar 3 
years EFS and OS. Prior R treatment, early relapse (<12 months) and higher IPI (2 or higher) 
have been shown to affect 3yrs EFS, PFS and OS. Data from R maintenance part of this trial 
is still maturing and may provide insight for future treatments. 
4.1.2 Follicular lymphoma  
Follicular lymphomas (FL) are considered incurable with standard chemotherapeutic 
options (Cheson  et al 2007). Multiple phase III trials have shown improvement in PFS as 
well as OS in low-grade B cell lymphoma when treated with R.  
Initial study by Czuczman et al reported 95% overall RR (55% CR, 40% PR). 74% patients 
remained in remission at the end of median follow up of 29 months (Czuczman et al 
1999). German Low-Grade Lymphoma Study Group (GLSG) conducted a larger study 
with untreated advanced-stage FL randomized to R-CHOP versus CHOP (Hiddemann et 
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al 2005). Overall RR was higher in R-CHOP arm compared to CHOP only arm (96% vs 
90%, p=0.011), though CR rates were not statistically significant (20% vs 17%). 
Importantly, after median follow up of 18 months, 28 patients relapsed in R-CHOP arm 
compared to 61 patients in CHOP arm, resulting in significant risk reduction by 60% and 
longer time to failure (p<0.001), as well as longer duration of response (p=0.001). This 
benefit was extended to all subgroups irrespective of IPI status and age. R in combination 
with interferon and chemotherapy  in patients with high tumor burden was reported to 
have improved disease control with fewer treatments(Salles et al 2008). East German 
Study Group Hematology and Oncology study reported improved survival with R 
combination (Herold, Haas et al. 2007).  
Based on the above trials R-CVP or R-CHOP has been established as a standard of care for 
advanced stage follicular lymphoma. R continues to be evaluated in combination with new 
agents.  
GLSG reported significantly higher overall RR, PFS and 2 year survival rates in combining R 
with chemotherapy in patients with relapsed/refractory FL (Forstpointner, Dreyling et al. 
2004). Another phase III trial reported similar results (van Oers et al 2006)- superior overall 
RR (85.1% vs 72.3%; P < .001) and CR rate (29.5% vs 15.6%; P < .001).  
Recently, PRIMA study reported R as maintenance therapy, after induction treatment, 
improved CR rates and PFS however there was no difference in OS (Salles, Seymour et al.).  
Similar findings were reported in MAXIMA trial phase IIIb update at ASH 210 meeting (Fao 
R et al).  These two trials have established a role for maintenance R in improving RR and 
FFS however there was no improvement in OS. 
The Watch and Wait study is a randomized phase III trial which enrolled patients with 
asymptomatic, non-bulky stage II, III and IV FL (Ardhesna et al)(Kirit M Ardeshna 2010). 
Primary end point of this study was to determine time to initiation of new systemic therapy, 
and quality of life. 462 Patients were randomly assigned with ratio of 1:1:1 to watchful 
waiting (arm A), R 375mg/m2 weekly for four weeks (arm B) or R 375mg/m2 weekly for 4 
weeks followed by MR every 2 months for 2 years (arm C). Median follow-up was 34 
months at the time of analysis. At three years, 49% of patients in watchful waiting did not 
receive any treatment, compared to 80% in R single agent (arm B) and 91% in MR (arm C). 
After three years, 30% of patients in watchful waiting group had not progressed compared 
to 60% in R single agent (arm B) and 81% in MR (arm C). Further follow-up did not reveal 
any difference in survival in either of the arms. Dr. Ardeshna concluded that R significantly 
improved both the time to initiation of new therapy and PFS.  
4.1.3 Rituximab in other lymphomas 
Rituximab has been evaluated in other lymphomas. R was added to hyper- 
CVAD (hyperfractionated cyclophosphamide/vincristine/doxorubicin/dexamethasone) 
alternating with high-dose methotrexate/cytarabine regimen for newly diagnosed 
patients with mantle cell lymphoma (MCL), Burkitt lymphoma and mature B-cell acute 
lymphoblastic lymphoma (Fayad, Thomas et al. 2007). Overall RR for MCL was 97% 
(CR/uCR 87%); 5 year FFS and OS were 48% and 65% respectively after median follow-up 
of 4.8 months. After median follow-up of 22 months overall RR for Burkitt’s lymphoma 
was 97% (CR 86%) with estimated 3-year OS, disease-free survival and EFS of 89%, 88% 
and 80% respectively (Fayad, Thomas et al. 2007). R also has shown activity in patients 
with relapsed indolent lymphoma or MCL in conjunction with bendamustine in a phase II 
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trial (Robinson, Williams et al. 2008). Overall RR was 92% (CR 41%, uCR 14%, and PR 
38%). Median duration of response and PFS were 21 months (95% CI, 18 to 24 months)  
23 months (95% CI, 20 to 26 months) respectively. Outcomes were similar for patients 
with indolent or mantle cell histologies (Robinson, Williams et al. 2008). Recently, R  
with bendamustine has shown significant RR including CR, as well as rapid and  
durable responses in patients with Waldenstorm macroglobulinemia (Treon, Ioakimidis  
et al. 2009).  
4.2 mTOR inhibitors 
Details regarding the pathway are mentioned above in MM part of this chapter. MCL is an 
aggressive NHL with cyclin D1 over-expression, which remains target for these mTOR 
inhibitors. The rapamycin analogues, everolimus and temsirolimus, are approved for 
treatment of renal cell cancer and have shown activity in lymphoma in pre-clinical models 
(Jundt, Raetzel et al. 2005). 
A phase II study evaluated role of everolimus as a single agent in patients with relapsed 
aggressive lymphoma (DLBCL 61%, MCL 25%, FL-III 10%)(Witzig, Reeder et al.). Overall 
RR was 30% (20PR/3uCR). Median duration of response was 5.7 months, and 5 patients 
remained disease free at 12 months.  A study is currently recruiting patients to determine 
whether everolimus plus R is safe and effective in patients with relapsed or refractory 
DLBCL (NCT00869999) .  
Temsirolimus was initially studied in relapsed MCL as a single agent (Witzig, Geyer et al. 
2005). ORR was 38% (3% CR, 35% PR). The median time-to-progression was 6.5 months; 
with duration of response of 6.9 months.  A recent phase III study randomized 162 patients 
with relapsed or refractory MCL to 1:1:1 to receive one of two temsirolimus regimens: 175 
mg weekly for 3 weeks followed by either 75 mg (175/75-mg) or 25 mg (175/25-mg) weekly, 
or investigator's choice therapy from prospectively approved options (Hess, Herbrecht et al. 
2009). Overall RR was 22%, 6% and 2% in 175/75-mg, 175/25-mg, and investigator's choice 
groups, respectively. Median PFS was 4.8 (175/75-mg), 3.4 (175/25-mg), and 1.9 months 
(investigator's choice groups, p=0.0009 vs 175/75 mg). Patients treated with temsirolimus 
175/75-mg had significantly longer PFS than those treated with investigator's choice 
therapy (P = .0009; hazard ratio = 0.44); those treated with temsirolimus 175/25-mg showed 
a trend toward longer PFS (P = .0618; hazard ratio = 0.65)(Hess, Herbrecht et al. 2009). 
Overall RR was significantly higher in the 175/75-mg group (22%) compared with the 
investigator's choice group (2%; P = .0019). Median OS for the 175/75-mg, 175/25-mg, and 
investigator’s choice groups was 12.8, 10 and 9.8 months respectively at the time of last 
update (Hess, Herbrecht et al. 2009).  
Deforolimus is a novel mTOR inhibitor which was studied in relapsed/refractory 
hematologic malignancies (Rizzieri, Feldman et al. 2008) and is undergoing clinical studies 
(NCT00086125). 
Preclinical studies have shown efficacy of mTOR inhibitors in Waldenstrom 
macroglobulinemia (WM), this was followed by a phase II trial (Ghobrial, Gertz et al.). 
Overall RR of 70% (42% PR, 28% minimal response, 0 CR) with estimated PFS at 6 and 12 
months of 75% and 62% were reported. Everolimus was also studied in relapsed Hodgkin’s 
lymphoma (HL) (Johnston, Inwards et al.). 19 patients with relapsed HL received 
everolimus with overall RR of 47% (1CR, 8PR) and a median duration of response of 7.1 
months (Johnston, Inwards et al.). 
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4.3 Radioimmunotherapy 
The efficacy of R can be augmented by “arming” the antibody with a radionuclide, toxin, or 
chemotherapeutic agent. In case of lymphomas, radioimmunotherapy (RIT) using CD20-
targeted immunoconjugates was developed. Two available RITs are: tositumomab/iodine I-
131 tositumomab (Bexxar) and Yttrium-90 –Labeled Ibritumomab Tiuxetan (Zevalin). 
Ibritumomab, the murine IgG1 anti-CD20 antibody that is the parent of the engineered 
chimeric antibody R, targets the same epitope on the CD20 antigen.  
A large randomized  phase III trial compared R to yttrium-90 (90Y) ibritumomab tiuxetan in 
143 patients with relapsed or refractory low-grade, follicular, or transformed CD20(+)  
transformed NHL (Witzig, Gordon et al. 2002).  Overall RR was 80% for the 90Y 
ibritumomab tiuxetan group versus 56% for the R group (P =.002). CR was higher in the 90Y 
ibritumomab tiuxetan arm compared to R groups (30% vs 16%, p=0.04). An additional 4% 
achieved an unconfirmed CR in each group. Median duration of response (14.2 mo vs 12.1 
mo, p=0.6) or TTP (11.2 mo vs 10.1 mo, p=0.30) were not significantly different.  
Another RIT 131I-Tositumomab was evaluated in treatment-naïve advanced stage FL 
(Kaminski, Tuck et al. 2005). Overall RR was 95% with CR of 75%. PFS was 59% and median 
PFS was 6.1 years with median follow-up of 5.1 years. Of 57 patients who had a CR, 40 
remained in remission for 4.3 to 7.7 years. Southwest Oncology Group (SWOG) conducted a 
phase II trial (SWOG 9911) of CHOP chemotherapy followed by 131I-Tositumomab 
consolidation for treatment-naïve advanced stage FL (Press, Unger et al. 2003). The overall 
RR was 90% (CR 67%, PR 23%). 27 of the 47 fully evaluable patients converted to CR 
following 131I-Tositumomab consolidation. With a median follow-up of 2.3 years, the 2-year 
PFS was estimated to be 81%, and 2-year OS was 97%. 5-year follow-up of this trial (Press, 
Unger et al. 2006) reported PFS was 67% and OS was 87%. The overall RR was 91%, 
including a 69% CR rate. Compared to historical group of patients in SWOG database who 
were treated with CHOP, the estimated 5-year OS and PFS were 23% better. Molecular 
remission was seen in 7 patients (18%) after CHOP and 24 additional patients (63%) after 
tositumomab/iodine I-131 tositumomab therapy (Press, Unger et al. 2006).  
Multiple other trials have compared RIT to fludarabine (Leonard, Coleman et al. 2005), CVP 
(Link, Martin et al.) or R-CHOP (Zinzani, Rossi et al. ; 2006) in first line treatment with 
excellent responses with CR between 60%-90%. Though, these treatments are very effective, 
they are still underutilized.  
4.4 Newer-generation anti-CD20 antibodies 
One of the newer generations of anti-CD20 antibodies is ofatumumab. This antibody is 
completely humanized IgG1 that recognized epitopes which are different than the ones 
recognized by R. Ofatumumab binds to a novel epitope of CD20, which encompass the 
small extracellular loop (residues 74 to 80) and the N-terminal region of the second large 
extracellular loop, including amino acid residues 163 and 166A (Teeling, Mackus et al. 2006). 
Coiffier et al published initial data on ofatumumab in patients with relapsed or refractory 
Chronic Lymphocytic leukemia (CLL) with RR of 50% and PFS of 106 days (Coiffier, 
Lepretre et al. 2008).  
Ofatumumab as a single agent was studied in patients with CLL refractory to fludarabine 
and alemtuzumab (FA-ref ) or refractory to fludarabine with bulky (> 5 cm) 
lymphadenopathy (BF-ref ) (William Wierda 2009). FA-ref patients had overall RR of 58%, 
median PFS of 5.7 months, and median OS of 13.7 months. BF-ref patients had RR 47%, 
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median PFS of 5.9 months and median OS of 15.4 months. Subgroup analysis continued to 
show response irrespective of prior anti-CD20 monoclonal antibody therapy with R, 
including refractoriness to fludarabine-based regimens containing R (William Wierda 2009). 
Ofatumumab was also proven effective in patients with treatment-naïve CLL with RR of 
72% and CR of 50% (William G Wierda 2009).  
Currently in development are : ocrelizumab, a 2H7 murine monoclonal antibody (Kausar, 
Mustafa et al. 2009); veltuzumab (Immu-106, hA20) also seeks target 2H7 (Morschhauser, 
Leonard et al. 2009); obinutuzumab (GA101) which recognizes a different epitope 
(Niederfellner, Lammens et al.) 
4.5 Alemtuzumab 
Alemtuzumab (Campath®/MabCampath®; Bayer Schering Pharma, Berlin) is a fully 
humanized IgG1-type monoclonal antibody directed against CD52, a 
glycosylphosphatidylinositol-anchored cell surface glycoprotein expressed on human B and 
T cells, natural killer cells, eosinophils and macrophages (Treumann, Lifely et al. 1995). 
Initial pilot study by Osterborg et al confirmed activity as well as safely of alemtuzumab in 
patients with CLL (Osterborg, Fassas et al. 1996). A larger phase II study showed RR of 87% 
with 19% CR in 41 newly diagnosed patients with CLL(Lundin, Kimby et al. 2002). In recent 
update median TTF was determined at 28 months (range 4 to 102+ months) (Karlsson, Norin 
et al. 2006).  
A large phase III study (CAM307) randomized patients with newly diagnosed CLL to 
receive either alemtuzumab (30 mg iv tiw for 12 weeks) or chlorambucil (40 mg/m2 orally 
once every 28 days for up to 12 cycles) (Hillmen, Skotnicki et al. 2007). Alemtuzumab arm 
had significantly improved ORR (83%, Cr 24%) compared to chlorambucil arm (55%, CR 
2%) (p<0.0001). Median time to alternate therapy was also significantly prolonged with 
alemtuzumab (23.3 months vs 14.7 months, HR 0.54, p<0.0001) (Hillmen, Skotnicki et al. 
2007). This trial proved efficacy of alemtuzumab over purine analogues in treatment-naïve B 
cell CLL, and has been approved by FDA as a first line therapy.  
T cells have high expression of surface CD52 antigen, highest being in T-prolymphocytic 
leukemia (T-PLL) (Ginaldi, De Martinis et al. 1998).  A phase II open label study treated 27 
treatment-naïve Peripheral T-cell Lymphoma (PTCL) patients with CHOP in combination 
with alemtuzumab (CHOP-C) for 8 cycles (Gallamini, Zaja et al. 2007).  CR was achieved in 
17 (71%) patients. At a median follow-up of 16 months, 13 patients were disease free, with 
median duration of response of 11 months (Gallamini, Zaja et al. 2007).  
4.6 CD30 
Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma are the two most common 
tumors expressing CD30. Brentuximab vedotin (SGN-35) is a monoclonal antibody that 
delivers monomethyl auristatin E to HL cells and utilized an anti-CD30 antibody to induce 
cell death, improved overall RR in patients with relapsed/refractory HL who has previously 
undergone ASCT.  
Initial phase I trial reported excellent overall RR and tumor regression (Younes, Bartlett et al 
2010). This led to larger pivotal phase II single arm study in patients with relapsed or 
refractory HL post ASCT (Chen R et.al)(Robert Chen 2010). Overall RR was 75% (34% CR, 
40% PR) with tumor regression in 94% patients. Estimated 12-month OS was 88%. Currently 
a larger phase 3 study is ongoing to evaluate role of Brentuximab Vedotin (SGN-35) in 
patients at high risk of residual HL following ASCT (The AETHERA Trial) (NCT01100502).  
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Side effects: 
The ろtargetsわ on the cancer drugs are often present in normal tissues to which leads to 
side effects. Due to limited space, the side effects experienced commonly by the most 
frequently use targeted agents are presented in the following table. 
 
Target Drug Side effect
BCR-ABL Imatinib Nausea/vomiting, fluid retention with pleural 
effusions, ascites, pulmonary edema and weight 
gain, diarrhea, myelosupression (neutropenia 
and thrombocytopenia), skin toxicity  
Immunomodulatory 
drugs 
Thalidomide Teratogenic toxicity, constipation, peripheral 
neuropathy, skin rash, day time sedation with larger 
doses, increased risk of thromboembolic events 
 Lenalidomide Teratogenic toxicity, myelosupression 
(neutropenia, thrombocytopenia that is usually 
reversible), increased risk of thromboembolic 
events, diarrhea or constipation
Proteosome 
Inhibitor 
Bortezomib Fatigue, malise, weakness, nausea/vomiting, 
diarrhea, myelosupression (neutropenia and 
thrombocytopenia that is usually reversible), 
peripheral sensory neuropathy, orthostatic 
hypotension, fever
Histone deacetylase 
(HDAC) inhibitor 
Vorinostat Nausea/vomiting, diarrhea, myelosupression 
(anemia and thrombocytopenia), fatigue, cardiac 
toxicity (QTc prolongation), hyperglycemia, 
increased risk of thromboembolic events 
mTOR inhibitor Temsirolimus Fatigue, pruritus and pustular, acneiform skin 
rash, mucositis, hyperlipidemia, hyperglycemia, 
rarely bowel perforation, interstitial lung disease, 
renal toxicity, peripheral edema
CD20 receptor Rituximab Infusion related toxicities including anaphylaxis, 
tumor lysis syndrome, skin reaction ranging 
from pemphigus to toxic epidermal necrolysis, 
lymphopenia, rhinitis and dyspnea
CD52 receptor Alemtuzumab Infusion related reactions, increased incidence of 
opportunistic infections including Pneumocystis 
jiroveci, cytomegalovirus, herpes zoster, candida, 
Cryptococcus, myelosupression (neutropenia, 
rarely pancytopenia with marrow hypoplasia) 
Table 4. Side effects of targeted treatment 
5. Conclusion 
Targeted therapies have changed the era of cancer treatment and their development is 
rapidly making headway. As listed above many are becoming front line therapies in 
combination with chemotherapy. Imatinib and ATRA have dramatically changed the course 
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of treatment for patients with CML or APL respectively. In addition, rituximab has 
improved RR and OS in patients with B-Cell lymphoma. Many other such drugs have been 
listed above and more drugs are in development. It is very crucial to understand the 
pathways and ‘’find the right target’’ in specific diseases. This new knowledge about 
‘’targets’’ will hopefully help us choose personalized treatments for our patients one day, 
improving their survival with minimal impact on their quality of life. 
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